We report 2 cases of eruptive melanocytic lesions associated with sorafenib, a multikinase inhibitor FDA-approved for the treatment of advanced renal cell carcinoma. Understanding the development of this previously unknown side effect may provide further insight into sorafenib's mechanistic effects on tumors and normal tissues and into the development of pigmented lesions.
No takes yet. Share an insight, caveat, or question.
Kong et al. (2008) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: